No abstract

Oral communication abstractsConclusions: The reported second trimester amniocentesis culture failure rate is 0.2%-0.9% and previous reports showed the third trimester failure rate to be 10%. These data show that the culture failure rate increases from 24 weeks, is one order of magnitude higher than second trimester amniocentesis after 28 weeks and by term, just under one half of karyotypes fail. This has implications for confirming post 24 week CGH array results with karyotype and for optimally timing invasive testing and enable gestation specific counselling about failure rates. Further analysis of current QF-PCR and CGH-array failure rates in late amniocentesis is recommended.

Univariate analysis showed that gestation (p< < 0.001), birthweight (p< < 0.001) and rate of weight gain (p=0.001) inversely correlated with grade of ROP, but with multiple regression only gestation remained significant (p< < 0.001). Rate of weight gain correlated with gestation; this may explain findings in previous studies.

Objectives: Cavum septum pellucidum (CSP) is an important intracranial structure that is necessarily visualised during routine second trimester sonography. A small or a large CSP may suggest abnormal cerebral development. Therefore, determination of CSP volumes can be useful. However, consistency of sonographic measurements for this relatively small structure is a concern. For this purpose, we sought to assess the reliability of CSP volume measurements with three-dimensional ultrasound between 19-24 weeks of gestational age in structurally normal fetuses. Methods: Three-dimensional Virtual Organ Computer-aided Analysis (VOCAL) software was used to calculate the CSP volume from transabdominal multiplanar datasets obtained during 99 consecutive normal fetal ultrasound examinations within a single unit. Agreement among 3 independent observers with different experience levels of ultrasonography (year 2 obstetrics and gynecology resident, year 2 maternal-fetal medicine fellow, and maternal-fetal medicine specialist) was evaluated, using absolute agreement intraclass correlation coefficients (ICC) and 95% confidence intervals (CI). Results: Measurement of CSP volume was possible in all of the fetuses by all examiners. Interobserver agreement between fellow and specialist was relatively high (ICC, 0.78; 95% CI, 0.70-0.85), whereas limited ultrasound experience (resident) was associated with fair agreement with other observers (ICC for resident and specialist, 0.50; 95 CI%, 0.29-0.65 and ICC for resident and fellow, 0.57; 95% CI, 0.38-0.71). Conclusions: Three-dimensional ultrasound CSP calculations using VOCAL software between 19-24 weeks of gestational age seem feasible, but are reliable only when evaluated by an examiner with particular fetal sonography experience. Objectives: To analyse the outcome of fetuses detected with absence of a normal CSP in the last 5 years, in the Prenatal Diagnosis Unit of our tertiary centre. Methods: We performed a retrospective review of the cases with abnormal CSP evaluated in our tertiary unit, diagnosed between January 2012 and February 2016. The fetal anatomy was evaluated in all cases following the recommendations of the international guidelines. In abnormal CSP cases, fetal neurosonogram and an extended fetal anomaly scan were performed and amniocentesis was proposed to identify genetic disorders. Results: The absence of a normal CSP was observed in 0.49% of the cases (38/7740) examined for morphological purposes. Absent CSP was the initial observation that triggered further investigation and diagnosis of 7 cases with agenesis of corpus callosum and 2 septo-optic dysplasias. In heavily malformed brain cases, as the neural tube defects, hydrocephaly, porencephaly, schizencephaly and holoprozencephaly, the absence of CSP was only an observation, with less diagnostic importance and clinical implications. Almost half of the total abnormal CSP cases (16) associated genetic disorders, most of them with abnormal karyotype and all of them were associated with the absence of CSP. Cystic m...

Oral poster abstractsMethods: The combined test was offered to women carrying singleton pregnancies and attending their first prenatal visit before 13.0 weeks, in 10 centers in Catalonia, (the central site was Barcelona, and the other 9 were within a 110 km radius). If their estimated risk for trisomy 21 had an intermediate value (from 1/101 to 1/1000), women were asked to participate in the second step of a contingency test. After consent, they were referred before 14.0 weeks to a tertiary referral center in Barcelona, where 3 ultrasound markers (fetal ductus venosus, nasal bone and tricuspid regurgitation) were evaluated. Objectives: A common approach for trisomy 21 screening is the combination of NT measurement and first trimester PAPP-A and β-HCG taken at the same visit at 11-14 weeks (OSCAR test). Pregnancy associated plasma protein A (PAPP-A) is a first trimester marker of trisomy 21 and is particularly useful before 11 weeks whilst β-hCG is a better marker after 14 weeks. In order to maximise the potential of NT/biochemistry screening, we offered a model combining early PAPP-A measurement (9-10 weeks) with NT measurement (11 − 13 + 6 weeks) and early triple test (> 14 + 0 weeks) and audited its performance over 12-months in a tertiary fetal medicine unit. Results OP02.08Tricuspid regurgitation in screening pregnancies at 11 + 0 to 13 + 6 weeks of gestation T. Stefania, N. Cernea, E. Coleta Obstetrics and Gynecology, Emergency University Hospital, Craiova, RomaniaObjective: To investigate the performance of first-trimester screening for aneuploidies, but also for the pregnancy outcome, by including assessment of tricuspid blood flow in the combined test of maternal age, fetal nuchal translucency (NT) thickness and serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancyassociated plasma protein A (PAPP-A). Method: Screening by the combined test was performed in singleton pregnancies, between 11 + 0 to 13 + 6 weeks of gestation. In all cases tricuspid flow was assessed to determine if there was tricuspid regurgitation. It was noted as final parameters: chromosomal defects, fetal intrauterine demise, major cardiac anomalies, perinatal death. Results: Were included 727 pregnancies, 720 with chromosomally normal fetuses or the delivery of a phenotypically normal baby -euploid group, 5 with trisomy 21, 1with trisomy 18, 1 with trisomy 13. Tricuspid regurgitation was observed in 1,4% (10 cases) of the 720 euploid fetuses and 40% (2 cases) of the fetuses with trisomy 21 and in both cases of fetuses with trisomies 18 and 13. The prevalence increases for chromosomal defects, fetal death, and major cardiac anomalies if there is tricuspid regurgitation. It may be assumed that in a screening policy based on maternal age, fetal NT, serum free beta-hCG and PAPP-A, the assessment of tricuspid flow in all pregnancies would increase the detection rate of trisomies, and also could change the management of pregnancies with normal euploid babies. Conclusions: Assessment of tricuspid flow could improve the perfor...